1.Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19: a case report
Miki KOROKU ; Teppei OMORI ; Harutaka KAMBAYASHI ; Shun MURASUGI ; Tomoko KURIYAMA ; Yuichi IKARASHI ; Maria YONEZAWA ; Ken ARIMURA ; Kazunori KARASAWA ; Norio HANAFUSA ; Masatoshi KAWANA ; Katsutoshi TOKUSHIGE
Intestinal Research 2022;20(1):150-155
Coronavirus disease 2019 (COVID-19), caused by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is now a pandemic. Although several treatment guidelines have been proposed for patients who have both inflammatory bowel disease and COVID-19, immunosuppressive therapy is essentially not recommended, and the treatment options are limited. Even in the COVID-19 pandemic, adjuvant adsorptive granulocyte and monocyte apheresis may safely bring ulcerative colitis (UC) into remission by removing activated myeloid cells without the use of immunosuppressive therapy. Our patient was a 25-year-old Japanese male with UC and COVID-19. This is the first case report of the induction of UC remission with granulocyte and monocyte apheresis treatment for active UC associated with COVID-19.
Result Analysis
Print
Save
E-mail